At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
In Brief
A Phase 2 clinical trial evaluating radiation therapy, surgery, and 2 other interventions for Pancreatic Adenocarcinoma and Borderline Resectable Adenocarcinoma of the Head of the Pancrease. Targeting 126 participants across 155 sites in 2 countries.
Detailed Summary
This randomized phase II trial studies how well combination chemotherapy (mFOLFIRINOX) with or without hypofractionated radiation therapy before surgery works in patients with pancreatic cancer that can be removed by surgery. Drugs used in combination chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. It is not yet known if combination chemotherapy is more effective with or without hypofractionated radiation therapy before surgery in treating patients with pancreatic cancer.
Study Details
Timeline
Interventions
oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV
oxaliplatin IV, leucovorin IV and 5-FU IV